Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Thoracic 2Genitourinary 2Gastrointestinal 2Head & Neck 1CNS 1

Conditions

Breast Neoplasms 4Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × paclitaxel poliglumex × Breast × Clear all
NCT01227408 2017-05-02

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

University of Southern California

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT00265733 2016-12-06

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
48 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00270907 2013-02-13

CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
13 enrolled
Breast

Breast Neoplasms

NCT00148707 2007-12-21

Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
45 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡